ReportsCash, cash equivalents and marketable securities were $511.8 million as of June 30 .”We continue to make strong progress on our cardiac and skeletal muscle programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “We look forward to sharing important updates on both our EDG-7500 and sevasemten programs over the coming months.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- 3 Best Stocks to Buy Now, 7/29/2024, According to Top Analysts
- 3 Best Stocks to Buy Now, 7/26/2024, According to Top Analysts
- ‘Don’t Be Scared of Heights’: J.P. Morgan Suggests 2 Stocks to Buy
- Edgewise Therapeutics participates in a conference call with Piper Sandler
- Wedbush reveals three potential buyout targets for Biogen